ALDH1 and CD44 Expression: Potential Cancer Stem Cell Marker for Differentiating Endometrial Lesions and is Associated With Poor Outcomes in Patients With Endometrial Carcinoma
碩士 === 國防醫學院 === 病理及寄生蟲學研究所 === 104 === Aim: Cancer stem cells play essential roles in tumor metastasis and contribute to remarkably negative clinical outcomes. Recently, aldehyde dehydrogenase (ALDH1) and CD44 positivity was identified as a marker of breast cancer stem cells. We evaluated expressio...
Main Authors: | MA,PEI-LING, 馬珮羚 |
---|---|
Other Authors: | CHAO,TAI-KUANG |
Format: | Others |
Language: | zh-TW |
Published: |
2016
|
Online Access: | http://ndltd.ncl.edu.tw/handle/zzb826 |
Similar Items
-
The combination of aldehyde dehydrogenase 1 (ALDH1) and CD44 is associated with poor outcomes in endometrial cancer.
by: Hsin-Hui Huang, et al.
Published: (2018-01-01) -
ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas
by: Vei Mah, et al.
Published: (2021-06-01) -
Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma
by: Iris Rabinovich, et al.
Published: (2018-09-01) -
CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis
by: Anna Torres, et al.
Published: (2019-04-01) -
Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma
by: Mianxin Chew, et al.
Published: (2020-06-01)